Pfizer (PFE) investor relations material

Strategic portfolio evolution and commercial focus

• Refocused resources on high-potential products and key markets, cutting unproductive investments and improving commercial efficiency.

• New and reacquired products grew from $0.5B in 2023 to $4B, while OpEx was significantly reduced.

• COVID franchise was scaled down from $11B in 2024 to a $4B guidance for 2026, reallocating efforts to new growth platforms.

• Sales organization productivity tripled in three years through focused deployment and advanced analytics.

• Commercial models now emphasize targeted launches and resource allocation in top-performing countries.

Pipeline development and growth outlook

• 31 phase III clinical studies are ongoing, with a pipeline structured around areas of competitive strength, especially oncology.

• Growth is driven by both new launches and pipeline maturation, with $13B in new/acquired product sales and strong market share gains in key therapies.

• Oncology pipeline targets high-impact tumor types, leveraging established commercial and medical infrastructure.

• Chronic weight management and GLP-1 assets are prioritized, with a portfolio approach to address diverse patient needs.

• Portfolio management now emphasizes early signals and swing factors to optimize capital allocation and accelerate promising assets.

Market dynamics and pricing environment

• Most Favored Nation (MFN) agreements reduced tariff risks and prompted global moves toward fairer innovation pricing.

• Governments in the UK and Japan are adjusting policies to better support innovative medicines, including inflation adjustments and reduced clawbacks.

• The rise of China as a biotech powerhouse is reshaping the global landscape, with 50% of ADC and bispecific clinical studies now run in China.

• European and Japanese innovation is challenged by talent migration to the US, driven by better pricing and recognition.

• Regulatory and patent reforms in Europe are improving the environment for biotech and pharma innovation.